Company Cash Funds: unitybiotechnology.com (UBX)

Unity Bio (UBX) - corporate logo

Unity Biotechnology (UBX) pricing power potential depends on FDA approval of its joint and vision drugs. The cash volume trend clearly demonstrates the company's liquidity, where 0.00 shows the current value of the metric. Unity Biotechnology (UBX) develops senolytics to combat aging, targeting the massive regenerative medicine market. Meanwhile, the laboratories are implementing zero-waste synthesis methods to reduce water consumption.

Company Cash Reserve: Unity Biotechnology Inc. (UBX) for 07/04/2022 - 07/19/2025

Summary analytical data breakdowns for Unity Bio (UBX)

- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
Comprehensive company analysis:Unity Biotechnology
Product sample of Unity Biotechnology Inc.

Unity Biotechnology is tapping into the colossal regenerative medicine market by developing therapies for age-related pathologies. This cash balance figure demonstrates the company's ability to fund costly senolytic research and development without external support. The metric captures the actual liquidity remaining in accounts, excluding illiquid assets. Comparing these funds with the burn rate reveals the risk of a cash shortfall. A stable capital reserve confirms the viability of the issuer's business model.

Competing companies

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|ocugen.com - Company Cash Volume|PACB - Company Cash Volume|BNTC: Company Cash Volume|Company Cash and Cash Equivalents DSGN|Company Cash Funds Rocket Pharmaceuticals|Company Cash on Hand 4DMT (FDMT)|Company Cash Volume LXEO|Company Liquid Assets Korro Bio Inc.|Company Cash Volume EDIT (Editas Medicine Inc)|SLN: Company Cash and Cash Equivalents|PRQR - Company Cash Funds|Company Liquid Assets codexis.com CDXS|SGMO: Company Cash Volume|Nautilus Biotechnology (NAUT) - Company Cash Volume|Company Cash Funds Metagenomi, Inc|precisionbiosciences.com (DTIL) - Company Liquid Assets|Company Cash Funds Generation Bio Co. (GBIO)|Company Liquid Assets Boundless Bio, Inc.|Company Cash Funds Exicure, Inc. XCUR|IMNN: Company Cash and Cash Equivalents|PHIO - Company Cash Funds|Company Liquid Assets Mustang Bio MBIO|RNAZ: Company Cash Volume|Company Cash Position Bionano Genomics Inc. BNGO|APDN (Applied DNA Corp) - Company Cash Volume|bluebirdbio.com (BLUE) - Company Liquid Assets|Company Cash Volume IPA|Company Cash Volume Omega (OMGA)|Company Cash Funds Singular Genomics Systems Inc OMIC|Company Cash Volume Regulus RGLS|syros.com - Company Cash Volume|TBIO: Company Cash Funds|TCON: Company Cash Volume